PCM
Portolan Capital Management’s Castle Biosciences CSTL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $30.4M | Buy |
1,489,572
+224,349
| +18% | +$4.58M | 1.91% | 12 |
|
|
2025
Q1 | $25.3M | Buy |
1,265,223
+488,644
| +63% | +$9.78M | 1.93% | 11 |
|
|
2024
Q4 | $20.7M | Sell |
776,579
-479,049
| -38% | -$12.8M | 1.39% | 20 |
|
|
2024
Q3 | $35.8M | Buy |
1,255,628
+44,676
| +4% | +$1.27M | 2.6% | 6 |
|
|
2024
Q2 | $26.4M | Buy |
1,210,952
+167,542
| +16% | +$3.65M | 2.17% | 10 |
|
|
2024
Q1 | $23.1M | Buy |
1,043,410
+314,757
| +43% | +$6.97M | 1.76% | 14 |
|
|
2023
Q4 | $15.7M | Buy |
728,653
+475,625
| +188% | +$10.3M | 1.37% | 17 |
|
|
2023
Q3 | $4.27M | Sell |
253,028
-178,446
| -41% | -$3.01M | 0.4% | 77 |
|
|
2023
Q2 | $5.92M | Buy |
431,474
+174,825
| +68% | +$2.4M | 0.52% | 58 |
|
|
2023
Q1 | $5.83M | Sell |
256,649
-327,067
| -56% | -$7.43M | 0.56% | 63 |
|
|
2022
Q4 | $13.7M | Buy |
583,716
+283,126
| +94% | +$6.66M | 1.36% | 24 |
|
|
2022
Q3 | $7.84M | Buy |
300,590
+145,622
| +94% | +$3.8M | 0.83% | 41 |
|
|
2022
Q2 | $3.4M | Buy |
+154,968
| New | +$3.4M | 0.34% | 93 |
|
|
2021
Q3 | – | Sell |
-9,127
| Closed | -$669K | – | 136 |
|
|
2021
Q2 | $669K | Buy |
+9,127
| New | +$669K | 0.05% | 125 |
|
|
2021
Q1 | – | Sell |
-16,573
| Closed | -$1.11M | – | 162 |
|
|
2020
Q4 | $1.11M | Sell |
16,573
-11,059
| -40% | -$743K | 0.1% | 133 |
|
|
2020
Q3 | $1.42M | Sell |
27,632
-44,202
| -62% | -$2.27M | 0.16% | 125 |
|
|
2020
Q2 | $2.71M | Sell |
71,834
-63,820
| -47% | -$2.41M | 0.31% | 101 |
|
|
2020
Q1 | $4.04M | Sell |
135,654
-169,924
| -56% | -$5.07M | 0.61% | 53 |
|
|
2019
Q4 | $10.5M | Buy |
305,578
+180,647
| +145% | +$6.21M | 1.06% | 37 |
|
|
2019
Q3 | $2.26M | Buy |
+124,931
| New | +$2.26M | 0.25% | 77 |
|